Result for
Topic: Testing and Treatment
February 6, 2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
In vitro assessments of existing antivirals and selected other drugs found that remdesivir and chloroquine could be effective against 2019-nCoV. Remdeivir is noted as an inhibitor of viral reproduction that is already in clinical development for other severe viral illnesses (e.g., ebola and SARS), whereas chloroquine – a well-established antimalarial – might act by preventing…
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, et al. review reasons not to use corticosteroids for treatment of 2019-nCoV, following WHO advice against their use in cases of novel coronavirus. Reasons are based on similarities in the biology and clinical presentation of 2019-nCoV, SARS, and MERS. An addition to other negative clinical outcomes described based on earlier studies, use of corticosteroid…
February 5, 2020
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Using BenevolentAI, knowledge of coronavirus receptors, and assumptions about vulnerable cell types, Richardson, et al. assess AP2-associated protein kinase 1 (AAK1) inhibitors for potential 2019-nCoV therapeutic use. They identify baricitinib as a candidate for trials based on its plasma concentration at therapeutic doses. Richardson, et al. (Feb 3, 2020). Baricitinib as potential treatment for 2019-nCoV…
Machine intelligence design of 2019-nCoV drugs
Gao, et al. apply a generative network complex (GNC) machine intelligence approach to identify candidate protease inhibitors for treating 2019-nCoV, including an assessment of two HIV protease inhibitors. The GNC identifies 3-dimensional (3-D) drug candidates based on elements that include structure generation and property prediction algorithms. Molecule generation includes assessment of properties like binding affinity…
Previous page